Rocket Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Rocket Pharmaceuticals, INC.

Rocket Pharmaceuticals, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker RCKT. For European investors, it fits the profile of a specialty biopharma company focused on rare, severe, and often life-threatening diseases, where value creation is driven primarily by clinical data, regulatory milestones, and, increasingly, commercialization rather than by broad commercial penetration. Founded in 1999, Rocket has spent years building an integrated gene-therapy platform that spans discovery, clinical development, and manufacturing capabilities. The company’s core R&D and corporate headquarters are in Cranbury, New Jersey, with an additional corporate presence in New York. Rocket describes itself as a fully integrated biotechnology company, and in 2026 it crossed an important threshold by securing accelerated approval for KRESLADI™ in severe leukocyte adhesion deficiency-I (LAD-I). That approval gives the group its first marketed product, but the investment case is still dominated by the strength, breadth, and execution risk of the pipeline. Rocket’s competitive positioning rests on disease-modifying gene therapies designed to address the underlying genetic defect, not just symptoms. The company’s most important programs are concentrated in cardiovascular genetics and rare hematology/immunology. In cardiovascular disease, the key assets include RP-A501 for Danon disease, RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-associated dilated cardiomyopathy. In hematology/immunology, KRESLADI targets severe LAD-I, while the company also has legacy and earlier-stage programs in Fanconi anemia and pyruvate kinase deficiency. This focused pipeline gives Rocket several shots on goal, but it also leaves the investment thesis exposed to small patient populations, complex trial design, manufacturing demands, and regulatory uncertainty. From an industry standpoint, Rocket is competing in the high-science rare-disease gene-therapy arena, where credibility in clinical execution and CMC quality is crucial. The company has benefited from various regulatory designations over time, which can support development speed but do not eliminate risk. Recent highlights through 2025 and 2026 include the FDA lifting the clinical hold on the pivotal RP-A501 Danon study, the resumption of dosing, the FDA acceptance and subsequent approval path for KRESLADI, and the monetization of a Rare Pediatric Disease Priority Review Voucher for $180 million, which improved liquidity and reduced near-term financing pressure. Overall, Rocket Pharmaceuticals remains a high-beta rare-disease biotech with meaningful upside optionality, but also substantial dependence on execution across a concentrated pipeline.